Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting Non-phase study NCT06697626

Validation of a Novel Functional Food Designed to Meet the Nutritional Needs of People Living With Parkinson’s Disease

Validation of a Novel Functional Food Designed to Meet the Nutritional Needs of People Living With Parkinson’s Disease — Active Not Recruiting • Non-phase study • Neurology •…

📅 01 Jul 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Non-phase study
NCT ID
NCT06697626
Start
2024-11-14
Completion
2026-04-17
ClinicaliQ Trial Snapshot
  • Validation of a Novel Functional Food Designed to Meet the Nutritional Needs of People Living With Parkinson’s Disease — Active Not Recruiting • Non-phase study • Neurology • NCT06697626.
  • A 12-week study testing a specially designed drink with added fibre and vitamins to improve constipation and quality of life in Parkinson's disease patients.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Constipation is a common complication and non-motor symptom of Parkinson's disease (PD) and affects up to 80% of people with PD. It is in fact within the non-motor symptoms that nutrition and dietetic intervention could have the greatest impact. Research suggests that increasing the amount of fibre in the diet could help to alleviate the effects of constipation. Inulin is a type of fibre widely found in a variety of vegetables, and recent studies have shown that inulin can improve constipation in people with PD. With the assistance of a…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My son can now enjoy life’: Children with severe form of epilepsy helped by new drug
Neurology · BBC Health · 04 Mar 2026
Fenfluramine has demonstrated clinical benefit in children with Dravet syndrome, a severe and treatment-resistant form of early-onset epilepsy, with families reporting significant…
View brief →
Clinical Brief
Smart beds and motion sensors – is this the future of dementia care?
Neurology · BBC Health · 20 Sep 2026
Key takeaways for clinical practice: Smart home technology including motion sensors, bed monitors, and wearable devices (socks) can enable remote monitoring of…
View brief →
Clinical Brief
Anaemia and the new dementia link
Neurology · BBC Health · 07 May 2026
Key Takeaways for Clinical Practice Anaemia has been identified as a newly recognised risk factor for dementia, suggesting haemoglobin levels should be…
View brief →
Clinical Brief
Nobel Prize awarded for revealing inner workings of the brain
Neurology · BBC Health · 05 Oct 2026
Karl Deisseroth, Peter Hegemann, and Georg Nagel have been awarded the Nobel Prize for developing optogenetics, a technique enabling precise control of…
View brief →
Clinical Brief
Sisters with life-limiting condition taking NHS fight to Parliament
Neurology · BBC Health · 22 Sep 2026
Two sisters with life-limiting neurological condition are escalating NHS access dispute to parliamentary level, highlighting potential gaps in NHS service provision for…
View brief →
Guideline
Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years
Neurology · 16 Sep 2026
Mirdametinib is indicated for symptomatic and inoperable plexiform neurofibromas in children aged 2-17 years with neurofibromatosis type 1 (NF1); confirm diagnosis and…
View guideline →